Oak Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Oak Associates’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-81,050	Closed	-$625K	–	191
2014 Q4	$625K	Hold	81,050	–	–	0.07%	126
2014 Q3	$605K	Sell	81,050 -50,550	-38%	-$469K	0.07%	128
2014 Q2	$1.27M	Buy	131,600 +5,000	+4%	+$44.6K	0.16%	105
2014 Q1	$1.05M	Buy	126,600 +34,900	+38%	+$299K	0.13%	108
2013 Q4	$774K	Buy	+91,700	New	+$773K	0.08%	120

Other funds holding PDLI

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Oak Associates's PDLI Position: Q1 2015 in Review

Oak Associates sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 81,050 shares — an estimated $625K sold.

Oak Associates first reported a position in PDLI in Q4 2013 and held it in 5 quarters. The position peaked at $1.27M in Q2 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

Oak Associates reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
Oak Associates sold 81,050 PDL BioPharma, Inc. shares in Q1 2015, an estimated $625K.
Oak Associates first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 5 quarters.
Oak Associates's PDL BioPharma, Inc. position peaked at $1.27M in Q2 2014.
215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on Oak Associates's 13F filing for Q1 2015, filed 11 May 2015.